Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

  • STATUS
    Recruiting
  • End date
    Jul 1, 2028
  • participants needed
    50
  • sponsor
    University of Washington
Updated on 9 April 2022
ct scan
cancer
lymphoma
growth factor
cytopenia
doxorubicin
neutrophil count
tumor cells
pembrolizumab
bleomycin
avid
dacarbazine
vinblastine
adriamycin

Summary

This phase II trial studies the side effects of doxorubicin hydrochloride, pembrolizumab, vinblastine, and dacarbazine in treating patients with classical Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with pembrolizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving doxorubicin hydrochloride, pembrolizumab, vinblastine, and dacarbazine may work better in treating classical Hodgkin lymphoma.

Description

OUTLINE

PART A: Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine IV, and dacarbazine IV on days 1 and 15. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of cycle 1 and on day 15 of cycle 2. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.

PART B: Patients receive doxorubicin hydrochloride IV, vinblastine IV, dacarbazine IV, and pembrolizumab IV as in part A, but undergo a total of 6 treatment cycles.

After completion of study treatment, patients are followed up at 30 days and then up to 5 years.

Details
Condition Classical Hodgkin Lymphoma
Treatment laboratory biomarker analysis, doxorubicin hydrochloride, Pembrolizumab, dacarbazine, Vinblastine
Clinical Study IdentifierNCT03331341
SponsorUniversity of Washington
Last Modified on9 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must have cHL that has not been previously treated
Part A: Any stage
Patients must have measurable FDG-avid disease defined by standard criteria (Lugano 2014) and a minimum of 1.0 cm in diameter
Part B: Must be stage 3 or 4
Patients must be appropriate candidates for at least 2 cycles of doxorubicin
Patients should not have evidence of active central nervous system lymphoma
hydrochloride (adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) (6
cycles for Part B patients) or doxorubicin hydrochloride, vinblastine
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Patients must have a left ventricular ejection (LVEF) >= 50% within 56 days of enrollment
dacarbazine (AVD) (this could include patients ranging from favorable risk
early stage disease to poor prognosis advanced stage disease)
Absolute neutrophil count (ANC) >= 1,500/mm^3 (without transfusion or growth factor support)
Platelets >= 100,000/mm^3 (without transfusion or growth factor support)
Patients must have adequate labs within 10 days of treatment
All patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines
Male subjects should agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
Hemoglobin >= 8 g/dL. Growth factor and/or transfusion support is permissible to stabilize participant prior to study treatment if needed. There is no lower limit to cytopenias if related to bone marrow involvement
Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Serum creatinine < 1.5 mg/dl or creatinine clearance greater than 30/ml per minute by Cockcroft Gault formula
Total bilirubin =< 1.5 times upper limit of normal OR direct bilirubin =< upper limit of normal (ULN) for participants with total bilirubin levels > 1.5 x ULN
Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal (=< 5 x ULN for participants with liver metastases)
Patients must be anticipated to complete all planned study therapy

Exclusion Criteria

Patients known positive for human immunodeficiency virus (HIV), or infectious hepatitis type B or C
Pregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Patients with other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or other cancer from which the patient has been disease-free for 5 years or greater, unless approved by the protocol chair or co-chair
Patients who have other medical conditions that would contraindicate treatment with aggressive chemotherapy (including active infection, uncontrolled hypertension, congestive heart failure, unstable angina pectoris, or myocardial infarction within the past 6 months, uncontrolled arrhythmia, severe pulmonary disease or requirement of supplemental oxygen)
Active ischemic heart disease or congestive heart failure
Concurrent use of other anti-cancer agents or experimental treatments
Known current or prior autoimmune disease with the exception of vitiligo
Active or prior history of pneumonitis/interstitial lung disease that required corticosteroids
Current use of supplemental oxygen
Is known to have received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Administration of killed vaccines is allowed
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note